What You Should Know
- Digital healthcare leader iRhythm Holdings, Inc. has entered into a definitive agreement to acquire Vital Connect, Inc. for approximately $287.5M.
- The transaction consideration consists of $237.5 million in cash (funded from iRhythm’s balance sheet) and $50M in iRhythm common stock, with up to $30M in interim working capital financing provided prior to closing.
- The acquisition expands iRhythm’s flagship Zio cardiac monitoring portfolio by adding VitalConnect’s FDA-cleared platform, which supports mobile cardiac telemetry (MCT), inpatient monitoring, and biosensors tracking up to 11 physiological parameters.
- Expected to close by the end of 2026, the deal is projected to be accretive to iRhythm’s revenue growth rate beginning in 2027 while maintaining its target adjusted EBITDA margin of 15% in 2027.
Cardiac Monitoring: iRhythm Scales Biosensor Platform Across Hospital and Home Settings
iRhythm Holdings has entered into a definitive agreement to acquire privately held wearable biosensor company VitalConnect for approximately $287.5 million. The purchase price comprises $237.5 million in cash funded from iRhythm’s balance sheet and $50 million in iRhythm common stock, with iRhythm providing up to $30 million in interim working capital financing prior to close.
The acquisition addresses a structural gap in enterprise cardiology: the friction of relying on single-modality diagnostic tools across varying patient acuity levels. While iRhythm’s flagship Zio patch excels at long-term continuous ECG monitoring, health systems frequently require broader clinical modalities—including short-term Holter, mobile cardiac telemetry (MCT) with live look-in capabilities, and multi-vital sign tracking across inpatient, outpatient, and hospital-to-home settings.
VitalConnect’s FDA-cleared platform brings a 4-in-1 wearable biosensor capable of continuous monitoring for up to 30 days and tracking up to 11 physiological parameters. By integrating VitalConnect’s technology into its commercial scale and EMR-integrated infrastructure, iRhythm extends its reach beyond traditional ambulatory arrhythmia detection into acute inpatient telemetry, post-surgical recovery, and continuous remote patient monitoring.
The transaction is expected to close by the end of 2026, subject to customary closing conditions and regulatory approvals. iRhythm projects the deal will accelerate its top-line revenue growth profile beginning in 2027 while maintaining its target adjusted EBITDA margin of 15% for 2027.
“This combination represents a significant next step in iRhythm’s evolution from ambulatory cardiac monitoring to a broader cardiac monitoring and intelligence platform,” said Quentin Blackford, President and CEO of iRhythm. “VitalConnect adds complementary mobile cardiac telemetry, multi-vitals and hospital monitoring capabilities that complement Zio and meaningfully expand the categories of patients and customers we can serve.”
